CABASYR

CABASYR

CABASYR by Moldavian Pharma contains cabergoline, a long-acting dopamine receptor agonist used medically to reduce elevated prolactin levels. Official prescribing information and MedlinePlus describe cabergoline as a dopamine agonist indicated for hyperprolactinemic disorders in adults.

What CABASYR Is

The active ingredient in CABASYR is cabergoline. Cabergoline belongs to the dopamine agonist class and works by decreasing prolactin secretion from the pituitary. Official FDA labeling states that it is an ergot derivative indicated for treatment of hyperprolactinemic disorders, including idiopathic cases or those due to pituitary adenomas.

Cabergoline is not an anabolic steroid. It is a pharmaceutical dopamine agonist with a different mechanism and medical role. Its identity is defined by the active compound cabergoline and its prolactin-lowering action.

Active Ingredient

Cabergoline

Cabergoline is the defining ingredient in CABASYR. FDA labeling describes it as a long-acting dopamine receptor agonist, and MedlinePlus states that it lowers the amount of prolactin in the body.

Prolactin-lowering mechanism

The mechanism behind cabergoline is directly tied to prolactin regulation. The FDA label explains that prolactin secretion is mainly under inhibitory control by dopamine and that cabergoline exerts a direct inhibitory effect on prolactin secretion.

Medical Context

CABASYR is best understood as a cabergoline product intended for prolactin-related medical contexts, not as a general sports supplement. MedlinePlus lists cabergoline for hyperprolactinemia, and FDA labeling describes its use in adults with hyperprolactinemic disorders.

Because it is a regulated pharmaceutical ingredient, cabergoline should be viewed differently from ordinary sports nutrition products. It belongs to a prescription medication category in many markets and carries important medical considerations.

Important Safety Information

Cabergoline is a prescription drug and should not be treated like a casual supplement. Current FDA labeling recommends evaluation for valvular heart disease, including echocardiography, before initiating treatment, and states that the drug should not be used if valvular disease is detected.

The FDA label also advises against using cabergoline for suppression of normal postpartum lactation because of the risk of serious adverse reactions.

Sport and Regulatory Context

Cabergoline is best known from medical use in prolactin-related disorders rather than from sports supplementation. If buyers are subject to anti-doping rules or prescription-drug controls, local regulations and sport rules should be checked directly, because regulatory status can vary by jurisdiction and competition framework. FDA and MedlinePlus both present cabergoline as a drug product for medical use, not as an over-the-counter wellness item.

Summary

CABASYR by Moldavian Pharma contains cabergoline, a long-acting dopamine agonist used to lower prolactin in adults with hyperprolactinemic disorders. The core facts are the active ingredient, the dopamine agonist classification, and the medical context around prolactin regulation. It should be understood as a regulated pharmaceutical product with important safety considerations, not as a general supplement.

The product is available for sale to individuals and research institutions, laboratories, universities or chemical study circles intended to conduct research.

The product is not a food product or a dietary supplement, and is not suitable for human consumption.

If you feel unwell or experience side effects from contact with the substance, consult your doctor.

Special storage conditions:

Keep the undiluted vial of lyophilised powder in a cool, dry and dark place. After reconstitution, the substance should be stored at a temperature between 2 and 8 °C.

All of the above properties have been observed in laboratory studies not conducted on humans, and are intended for informational purposes only. None of the information contained in the descriptions is approved by the European Food Safety Authority (EFSA). This product is not a medicine, food or dietary supplement and is not suitable for human consumption. The product is classified as a chemical reagent/reference material authorised for use in the European Union and may only be used for scientific research. Other information about the product is contained in the safety data sheet, which we make available for inspection. The products are only available to institutions or individuals that are associated with research or laboratory activities.